In contrast, survivin inhibition has been reported to sensitize breast cancer cells to paclitaxel, etoposide, doxorubicin, and cisplatin (O’Connor et al., 2000; Wall et al., 2003; Mita et al., 2008; Lyu et al., 2018; Minaiyan et al., 2021); furthermore, survivin inhibition in combination with radiotherapy resulted in a significant decrease in lung cancer cells survival (Lu et al., 2004). This evidence concerns the gene BIRC5 and breast cancer.